Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;37(6):895-903.
doi: 10.1097/QAD.0000000000003478. Epub 2023 Jan 6.

Participation of HIV-1 infected treatment-naive females in clinical trials and sex differences in efficacy and safety outcomes

Shuang Zhou  1 , Karen Qi  2 , Bridget M Nugent  3 , Susan J Bersoff-Matcha  4 , Kimberly Struble  5
Affiliations

Participation of HIV-1 infected treatment-naive females in clinical trials and sex differences in efficacy and safety outcomes

Shuang Zhou et al. AIDS. .

Abstract

Objectives: To examine female participation and the observed efficacy and safety by sex from phase 3 HIV-1 trials submitted to the United States Food and Drug Administration (FDA) to support approval or a major labeling change.

Design: Our analyses were based on phase 3 trials in HIV-1 infected treatment-naive adults submitted to FDA since 2010.

Methods: We evaluated enrollment of treatment-naive females in 18 clinical trials for HIV-1. Participation to prevalence ratio (PPR) was calculated as the percentage of females among trial participants divided by the percentage of females in the disease population. PPR between 0.8 and 1.2 reflects similar representation of females in the trial and the disease population. Sex differences in efficacy (virologic response rates) and selected safety events were evaluated.

Results: United States (US) females, particularly US Black females were not adequately represented in clinical trials. The PPR for US females overall was 0.59 and for US Black females was 0.63. Statistically significant sex differences favoring males were observed for efficacy outcomes in both the global population and US participants. Statistically significant sex differences were observed for some safety outcomes.

Conclusions: US females are underrepresented in phase 3 HIV-1 clinical trials. Underrepresentation was not likely due to enrollment criteria. Statistically significant sex differences were noted for efficacy and selected safety outcomes; however, some differences were not clinically relevant. The ability to detect sex differences was hindered by low numbers of female participants overall and within subgroups. Additional research into innovative approaches to recruit and retain females in clinical trials should continue.

PubMed Disclaimer

Comment in

References

    1. UNAIDS. Fact sheet-world AIDS day 2021. Available at https://www.unaids.org/en/resources/fact-sheet
    1. Diagnoses of HIV Infection in the United States and Dependent Areas, 2019. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/hiv/statistics/overview/ataglance.html
    1. South EM, Zinn RL, Huang CJ, Vasisht KP. US Food and Drug Administration Office of Women's Health: promoting therapeutic optimization in women . J Clin Pharmacol 2020; 60: (Suppl 2): S11–S17.
    1. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. Female sex but not ethnicity is a strong predictor of nonnucleoside reverse transcriptase inhibitor-induced rash . AIDS 2002; 16:1566–1568.
    1. Hodder S, Arasteh K, De Wet J, Gathe J, Gold J, Kumar P, et al. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE . HIV Med 2012; 13:406–415.

Publication types

Substances